Literature DB >> 15490070

Optimizing the treatment of AMES high-risk papillary thyroid carcinoma.

Chung-Yau Lo1, Wai-Fan Chan, King-Yin Lam, Koon-Yat Wan.   

Abstract

A minority of patients with papillary thyroid carcinoma (PTC) is at high-risk of developing recurrent disease and death. Risk group stratification as defined by age, metastases to distant site, extrathyroidal invasion, and tumor size (AMES) criteria is frequently employed to identify high-risk patients for aggressive surgical and adjuvant treatments. The present study aimed at evaluating risk factors and the impact of treatment on cause-specific mortality (CSM) in this group of high-risk patients. From 1961 to 2000,150 of 499 patients surgically treated for PTC were considered as high-risk by AMES criteria. At 10-years CSM was significantly higher in high-risk patients (28%) than in low-risk patients (2%) (p < 0.0001). The clinicopathologic features, treatment, and outcome of AMES high-risk patients were retrospectively studied and risk factors for CSM were analyzed. There were 58 men and 92 women with a median age of 62 years (range: 18-87 years). Bilateral thyroidectomy was performed for 143 (95%) patients and concomitant neck dissection was performed for 82 patients (55%). Thirty-six patients (24%) underwent incomplete tumor excision with residual disease. Radioactive iodine (I131) ablation and external-beam irradiation were administered to 102 (68%) and 46 patients (31%), respectively. Over a median follow-up of 7.6 years, the overall mortality was 23% and 44%, whereas the CSM was 14% and 28% at 5 and 10 years, respectively. Using the Cox proportional hazard model, distant metastasis at presentation, incomplete tumor excision, and no postoperative I131 treatment were independent prognostic factors of poor survival. Patients who underwent an incomplete excision showed improved survival after I131 ablation (p = 0.0008), external-beam irradiation (p = 0.02), or both forms of treatment (p = 0.04). Within this high-risk AMES group, International Union Against Cancer (UICC) pTNM staging and MACIS (Metastasis, Age, Completeness, Invasion, Size) scoring correlated significantly with CSM. AMES high-risk PTC patients should undergo total thyroidectomy aiming at complete tumor resection followed by I131 ablation. External-beam irradiation should be added for patients with residual disease after an incomplete excision.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15490070     DOI: 10.1007/s00268-004-7420-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  32 in total

Review 1.  Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; R T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

2.  Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment.

Authors:  L E Sanders; B Cady
Journal:  Arch Surg       Date:  1998-04

3.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.

Authors:  D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke
Journal:  Eur J Cancer       Date:  1979-08       Impact factor: 9.162

4.  Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis.

Authors:  N F Esnaola; S B Cantor; S I Sherman; J E Lee; D B Evans
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

5.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Authors:  R W Tsang; J D Brierley; W J Simpson; T Panzarella; M K Gospodarowicz; S B Sutcliffe
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

6.  Value of external irradiation for locally advanced papillary thyroid cancer.

Authors:  Tae-Hyun Kim; Dae-Sik Yang; Kwang-Yoon Jung; Chul-Yong Kim; Myung-Sun Choi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-03-15       Impact factor: 7.038

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

8.  Papillary and follicular thyroid cancer: impact of treatment in 1578 patients.

Authors:  W J Simpson; T Panzarella; J S Carruthers; M K Gospodarowicz; S B Sutcliffe
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-06       Impact factor: 7.038

9.  Prognostic importance of various clinicopathological features in papillary thyroid carcinoma.

Authors:  L A Akslen; A O Myking; H Salvesen; J E Varhaug
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

10.  Further evidence of the validity of risk group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi; M Silverman; M Wool
Journal:  Surgery       Date:  1985-12       Impact factor: 3.982

View more
  8 in total

1.  Papillary microcarcinoma: is there any difference between clinically overt and occult tumors?

Authors:  Chung-Yau Lo; Wai-Fan Chan; Brian Hung-Hin Lang; King-Yin Lam; Koon-Yat Wan
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

2.  Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo; Wai-Fan Chan; Alfred King-Yin Lam; Koon-Yat Wan
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

3.  Adjuvant radioactive iodine use among differentiated thyroid cancer patients in the military health system.

Authors:  Abegail A Gill; Lindsey Enewold; Shelia H Zahm; Craig D Shriver; Li Zheng; Katherine A McGlynn; Kangmin Zhu
Journal:  Mil Med       Date:  2014-09       Impact factor: 1.437

Review 4.  Staging systems for papillary thyroid carcinoma: a review and comparison.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

5.  Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers.

Authors:  Brian Hung-Hin Lang; Sin-Ming Chow; Chung-Yau Lo; Stephen C K Law; King-Yin Lam
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

6.  Is minimal residual lymph node disease in papillary thyroid cancer of prognostic impact? An analysis of the epithelial cell adhesion molecule EpCAM in lymph nodes of 40 pN0 patients.

Authors:  Alexander Rehders; Martin Anlauf; Ilona Adamowsky; Markus H Ghadimi; Sarah Klein; Christina Antke; Kenko Cupisti; Nikolas H Stoecklein; Wolfram T Knoefel
Journal:  Pathol Oncol Res       Date:  2013-08-06       Impact factor: 3.201

7.  Pathological characteristics and clinical perspectives of papillary thyroid cancer: study of 714 patients.

Authors:  Davor Džepina; Krešo Zurak; Vlado Petric; Hrvoje Čupić
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-09       Impact factor: 2.503

8.  Risk-stratified management of well-differentiated thyroid cancers: a review of experience from a single institution, 1990-2003.

Authors:  M H Chew; G Chan; M M A Siddiqui; B C Tai; R Sivanandan; K C Soo; D T H Lim
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.